GlySure CEO to Present CE Mark Trial Results at OneMedForum 2014
OXFORD, England, January 7, 2014 /PRNewswire/ --
GlySure reaches major milestone in delivering continuous blood glucose monitoring (CBGM) technology to the healthcare marketplace
GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its European regulatory trial at the OneMedForum 2014 conference on January 13, 2014, in San Francisco.
OneMedForum 2014 will be the first time that the GlySure CEO Christopher Jones publicly presents the results of the multi-center CE Mark trial, which comprised 34 post surgery cardiac intensive care unit patients.
GlySure's announcement of the trial results marks the culmination of an exceptional year for the UK-based company. Since the start of 2013, GlySure has completed the development of the commercial version of its CBG monitor and sensor, secured ISO 13485 certification, completed a successful pilot trial on 24 cardiac ICU patients, recruited its European Director of Clinical Affairs, and delivered a successful European regulatory trial.
GlySure is currently compiling its CE Mark Technical File submission, which is the next step toward securing marketing approval of its CGBM technology in Europe. The company anticipates that it will make this submission in Q1.
"We are extremely pleased with the trial results demonstrating the ability to provide true continuous blood glucose monitoring on patients throughout their stay in cardiac intensive care," said GlySure CEO Christopher Jones. "We look forward to sharing these positive findings with the industry at OneMedForum in San Francisco next week."
OneMedForum 2014 will focus on areas of greatest investment opportunity in therapeutics, devices, diagnostics and health information and will also showcase the most promising microcap public companies and high growth private (pre-IPO) companies. More than 100 companies and 1,300 investors attend the annual event.
GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com
Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870, firstname.lastname@example.org
Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127, email@example.com